Duration of benefit from the published trial was not clearly reported beyond 3–6 months post-infusion. Fibromyalgia is a chronic condition with natural fluctuation in symptom severity, so distinguishing sustained improvement from placebo effect or disease-cycle variations is difficult without long-term controlled data.
Fibromyalgia is a disorder of central pain processing characterised by widespread musculoskeletal pain, fatigue, and sleep disturbance, often accompanied by cognitive difficulties ('fibro fog'). No primary tissue damage is evident; instead, dysregulation of pain-signal amplification in the spinal cord and brain—low serotonin, elevated substance P, sensitised pain receptors—perpetuates the syndrome. The condition predominantly affects women and is often triggered by trauma, infection, or stress. Cell therapy exploration in fibromyalgia is nascent; placental MSCs and their secreted exosomes are being investigated for immunomodulatory properties (shifting immune response away from pro-inflammatory cytokine production) and for potential neuromodulation through delivery of anti-inflammatory molecules to the central nervous system. The hypothesis is that systemic cellular or exosome infusion might dampen the amplified pain state and restore normal sleep and mood regulation.
Sunt un candidat? → · Fibromyalgia & Chronic Fatigue: full overview → · Cost Fibromialgie și Sindromul Oboselii Cronice → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită